We are a clinical stage biopharmaceutical company discovering and developing novel therapies for the treatment of fibrosis and related diseases. By leveraging our powerful product discovery engine, we are discovering and developing novel therapeutics that seek to halt progression of fibrosis in specific tissues— ultimately, preserving organ function.
We are combining world-class expertise in TGF-β signaling and integrin biology, medicinal chemistry, translational screening technologies, and clinical insights to create best-in-class, tissue-specific inhibitors of fibrotic diseases. Our pipeline has the potential to benefit numerous patient populations, as we are targeting a variety of organs and conditions including lung (IPF), liver (primary sclerosing cholangitis, NASH and liver fibrosis), muscle (Duchenne muscular dystrophy) and oncology.
Pliant was founded in 2015 by world-renowned researchers from the University of California, San Francisco, who have deep expertise in fibrosis biology and small-molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.
At Pliant Therapeutics, we’re driven to transform the lives of patients by developing best-in-class treatments for fibrotic diseases.
“Historically, fibrosis has been studied in silos. At Pliant, we have developed a comprehensive approach that has enabled us to better define pathological processes, identify the key molecular targets, and treat fibrosis. With this approach, we aim to transform the lives of patients with these debilitating diseases.”
– Bernard Coulie, M.D., Ph.D., president and CEO
Pliant Therapeutics, Inc.
260 Littlefield Avenue,
South San Francisco, CA 94080
info@pliantrx.com
650.481.6770